Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-036-7 | CAS number: 1478-61-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- endocrine disrupter mammalian screening – in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Remarks:
- The study was conducted to OECD 407
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- other:
- Version / remarks:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- Repeated dose toxicity in rats
- Limit test:
- no
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Not reported
- Stability under test conditions: Not reported
- Solubility and stability of the test substance in the solvent/vehicle: Confirmed
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: Not reported
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: Not reported
- Preliminary purification step (if any): Not reported
- Final dilution of a dissolved solid, stock liquid or gel: Not reported
- Final preparation of a solid: Not reported
FORM AS APPLIED IN THE TEST (if different from that of starting material): Not reported
OTHER SPECIFICS: n/a - Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crj:CD(SD)
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Crj:CD (SD) rats were purchased from Charles River, Japan, Inc (Shiga, Japan)
- Females (if applicable) nulliparous and non-pregnant: Not reported
- Age at study initiation: 8 weeks
- Weight at study initiation: ca. 310 - 340 g (males) and ca. 203 - 226 g (females)
- Fasting period before study: Not reported
- Housing: Housed individually in stainless stell wire-mesh cages.
- Diet (e.g. ad libitum): Ad libitum, commercial diet (MF, Oriental Yeast Co., Tokyo, Japan)
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: Not reported
DETAILS OF FOOD AND WATER QUALITY: Not reported
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 ºC
- Humidity (%): 55 ± 20 %
- Air changes (per hr): Not reported
- Photoperiod (hrs dark / hrs light): 12: 12 (light: dark)
IN-LIFE DATES: Not reported - Route of administration:
- oral: gavage
- Details on route of administration:
- The volume of the olive oil that contained the chemical for gavage was 5 mL/kg.
- Vehicle:
- olive oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): n/a
- Mixing appropriate amounts with (Type of food): n/a
- Storage temperature of food: n/a
VEHICLE
- Justification for use and choice of vehicle (if other than water): olive oil - OECD recommended to aid solubility of test item.
- Concentration in vehicle: Not reported
- Amount of vehicle (if gavage): 5 mL/kg/bw
- Lot/batch no. (if required): Not reported
- Purity: Not reported - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Dose / conc.:
- 30 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose selection rationale: Chosen after completition of a range-finder test. Concentrations did not induce death or severe suffering.
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: No
- Post-exposure recovery period in satellite groups: n/a
- Section schedule rationale (if not random): Males were necropsied on Day 29. Females were necropsied after having been dosed for at least 29 days and killed ondays 30–33 to allow them to be killed in the diestrous stage or in the continuous same stage. - Positive control:
- No
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
- Cage side observations checked in Table 2 were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Weekly
BODY WEIGHT: Yes
- Time schedule for examinations: Twice weekly and before necropsy
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): n/a
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: n/a
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: n/a
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): n/a
- Time schedule for examinations: n/a
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations: n/a
- Dose groups that were examined: n/a
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At termination
- Anaesthetic used for blood collection: Yes (chemical name not reported)
- Animals fasted: Not specified
- How many animals: 20 animals per treatment group (10 males and 10 females, 80 animals in total)
- Parameters checked in Table 3 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At termination
- Animals fasted: Not specified
- How many animals: 20 animals per treatment group (10 males and 10 females, 80 animals in total)
- Parameters checked in Table 3 were examined.
URINALYSIS: No
- Time schedule for collection of urine: n/a
- Metabolism cages used for collection of urine: n/a
- Animals fasted: n/a
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: 4th week after test initialtion
- Dose groups that were examined: Control, 10, 30 and 100 mg/kg bw/day
- Battery of functions tested: sensory activity / grip strength / motor activity.
IMMUNOLOGY: No
- Time schedule for examinations: n/a
- How many animals: n/a
- Dose groups that were examined: n/a
OTHER: Hormone analysis (in serum), estrous cycle, spermatology and histopathology observations were also undertaken. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes - Table 4
HISTOPATHOLOGY: Yes - Table 4 - Statistics:
- Bartlett’s variance test was performed for the parametric data (body weight, food consumption, hematological data, clinical biochemical data, hormonal data, organ weight, sperm count, grip strength, and locomotor activity). Bartlett’s test revealed a homogeneous variance, so one-way analysis of variance was conducted and if the result of the one-way analysis was significant, Dunnett’s test was performed to compare the treated and the control groups. Data with an inhomogeneous variance shown by Bartlett’s test or nonparametric data (the number of stools, the number of urinary pools, and incidence rate of abnormal spermatozoa) were subjected to the Kruskal–Wallis rank test, and if a significant divergence was observed, a Dunnett’s approach was carried out. Incidence rates of abnormal estrous cycles, gross pathological findings, and histopathological findings were analyzed by Fisher’s “exact” probability test. In the evaluation of the examination results, when a divergence from the control was found at a significance level of 1 or 5%, it was regarded as a significant change.
A male rat in the control group was diagnosed as being the subject of an administration error on gross and histopathological examination. The error was thought to have happened just before day 22, based on changes in body weights and food consumption, so data that contained body weights at days 26 and 28, food consumption at days 22 and 28, and all organ weights of this rat were excluded from the statistical analysis. - Endocrine disrupting potential:
- positive
- Maximum tolerated dose level exceeded:
- not specified
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Several male and female rats in the 100 mg/kg group showed salivation from the first week, and this sign disappeared within 90 min of administration. No other abnormal general findings were observed in any of the groups.
Salivation in the 100 mg/kg group was not found to be a sign of toxicity because this sign disappeared soon after administration and no other related changes were observed. - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A decrease in body weight gains was found in the male rat 100 mg/kg group and the female rat 30 and 100 mg/kg groups from the first week after administration and was accompanied by decreased food consumption.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- A decrease in body weight gains was found in the male rat 100 mg/kg group and the female rat 30 and 100 mg/kg groups from the first week after administration and was accompanied by decreased food consumption.
- Water consumption and compound intake (if drinking water study):
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In male rats, white blood cell counts, total cholesterol, and albumin values decreased in the 100 mg/kg group. In female rats, cholinesterase and total cholesterol values decreased and total bilirubin values increased in the 100 mg/kg group.
Serum T4 values increased in the 100 mg/kg groups of both sexes, but no changes in TSH were detected in any treated groups. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, the relative weights of kidney, adrenal, and brain increased signifcantly in the 100 mg/kg group and the absolute weights of prostate, ventral prostate, seminal vesicle, liver, heart, and spleen decreased in this group. In female rats, the relative brain weights increased significantly in the 30 and 100 mg/kg groups, and the absolute heart weights decreased in the 100 mg/kg group.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Dilatation of the large intestinal lumen was observed in 9 male and female rats in the 100 mg/kg groups, respectively.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In the male rats, the incidence of changes, such as atrophy of testicular Leydig cells, hypertrophy of the adrenal zona fasciculata, and decreased hepatocytic glycogen, was higher in the 100 mg/kg group than in the control group. In addition, decreased hematopoiesis in the bone marrow and spleen, atrophy of the mammary glands, and atrophy of pituitary basophilic cells were also observed in the 100 mg/kg group. In female rats, hypertrophy of the adrenal zona fasciculata and decreased hepatocytic glycogen were detected in several rats given the chemical.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 10 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- body weight
- organ weights
- gross pathology
- histopathology
- Conclusions:
- The no adverse effect level (NOAEL) for the test item was determined to be 10 mg/kg bw/day, due to findings of reduced body weight gain and abnormal estrous cycles in the female rat 30 mg/kg bw/day group.
- Executive summary:
In a subacute repeat dose toxicity study (OECD 407), Bisphenol AF was administered to 30 male and 30 female Sprague-Dawley rats by oral gavage at dose levels of 10, 30 and 100 mg/kg bw/day for up to 28 consecutive days. In addition, control rats were dosed with vehicle (olive oil) alone for each test group.
A summary of adult responses to Bisphenol AF is described below;
Mortality - no treatment-related deaths were detected.
Clinical signs - clinical signs were generally confined to post-dose increased salvation and staining around the mouth for animals treated at 100 mg/kg/day. Regression of all signs was evident 90 minutes after treatment.
Behavioural assessments - open field observations did not reveal any treatment-related effects.
Functional performance - no treatment-related effects were evident for grip or motor activity.
Sensory reactivity assessments - no treatment-related effects were observed.
Bodyweight - significant (p< 0.01) reduced bodyweight gains were evident for males in the 100 mg/kg/day group during the treatment period. For females, bodyweight gain was significantly (p <0.05) reduced in the 30 and 100 mg/kg/day groups.
Haematology and blood chemistry - for males, a significant reduction in white blood cell count (p < 0.05), cholinesterase and albumin (p < 0.01) was observed in the 100 mg/kg bw/day treatment group. Further, a significant (p < 0.01) increase in T4 hormone was also observed in the same treatment group. For females, a significant decrease in cholinesterase (p < 0.05) and total cholesterol (p < 0.01) was observed in the 100 mg/kg bw/day treatment group. Further, a significant (p < 0.01) increase in total bilirubin and T4 hormone was also observed in the same treatment group.
Oestrous cycle assessment - irregular estrous cycles were observed in the 30 and 100 mg/kg groups, and the diestrous stage continued in some animals. The mean duration of estrous cycles was prolonged in the 100 mg/kg group without statistical difference.
Necropsy - dilatation of the large intestinal lumen was observed in 9 male and female rats in the 100 mg/kg groups, respectively.
Organ weights - in males, the relative weights of kidney, adrenal, and brain increased significantly in the 100 mg/kg group and the absolute weights of prostate, ventral prostate, seminal vesicle, liver, heart, and spleen decreased in the same group. In female rats, the relative brain weights increased significantly in the 30 and 100 mg/kg groups, and the absolute heart weights decreased in the 100 mg/kg group.
Histopathological changes - in the male rats, the incidence of changes, such as atrophy of testicular Leydig cells, hypertrophy of the adrenal zona fasciculata, and decreased hepatocytic glycogen, was statistically significantly higher in the 100 mg/kg group than in the control group. In addition, decreased hematopoiesis in the bone marrow and spleen, atrophy of the mammary glands, and atrophy of pituitary basophilic cells were also observed in the 100 mg/kg group. In female rats, hypertrophy of the adrenal zona fasciculata and decreased hepatocytic glycogen were detected in several rats at each dose level, although these changes were not statistically significantly.
In conclusion, the No Observed Adverse Effect Level (NOAEL) for systemic toxicity was 10 mg/kg bw/day due to findings of reduced body weight gain and abnormal estrous cycles in the female rat treated at 30 mg/kg bw/day.
This subacute repeat dose toxicity study in the rat is acceptable and satisfies the guideline requirements for an OECD 407 in the rat.
Table 5 Mean body weight changes following 28 days of treatment
ose Group | Mean Initial Body Weight (g) | Mean Terminal Body Weight (g) | ||
Male | Female | Male | Female | |
Control | 324 ± 14 | 211 ± 7 | 449 ± 27 | 274 ± 18 |
10 mg/kg/day | 324 ± 13 | 215 ± 11 | 451 ± 26 | 277 ± 18 |
30 mg/kg/day | 325 ± 15 | 213 ± 10 | 450 ± 33 | 255 ± 18* |
100 mg/kg/day | 326 ± 13 | 214 ± 11 | 396 ± 29** | 253 ± 15* |
* statistically different from control group (p < 0.05)
** statistically different from control group (p < 0.01)
Table 6: Selected haematology, clinical chemistry and pathology findings
aily Dose (mg/kg bw/day) | Male | Female | ||||||
Control | 10 | 30 | 100 | Control | 10 | 30 | 100 | |
No. of animals | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Haematology | ||||||||
- WBC (x103/mm3) | 12.28 ± 1.05 | 11.83 ± 2.66 | 11.17 ± 2.67 | 9.17 ± 2.46* | 8.59 ± 2.49 | 9.06 ± 2.15 | 9.28 ± 1.77 | 8.90 ± 1.84 |
Blood chemistry | ||||||||
- Cholinesterase (IU/L) | 54 ±18 | 56 ± 19 | 48 ± 11 | 50 ± 10 | 525 ± 163 | 537 ± 98 | 465 ± 236 | 300 ± 127* |
- Total cholesterol (mg/dL) | 69 ± 8 | 60 ± 12 | 60 ± 9 | 49 ± 7** | 69 ± 12 | 65 ± 7 | 60 ± 11 | 47 ± 5** |
- Total bilirubin (mg/dL) | 0.03 ± 0.02 | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.03 ± 0.02 | 0.02 ± 0.01 | 0.01 ± 0.01 | 0.02 ± 0.01 | 0.04 ± 0.02** |
- Albumin (g/dL) | 3.00 ± 0.28 | 3.05 ± 0.12 | 3.05 ± 0.09 | 2.84 ± 0.11** | 3.51 ± 0.45 | 3.56 ±0.16 | 3.35 ± 0.33 | 3.30 ± 0.27 |
- T4 (ng/dL) | 3.704 ± 0.452 | 4.158 ± 0.826 | 4.061 ± 0.846 | 4.754 ± 0.762** | 2.397 ± 0.297 | 2.376 ± 0.443 | 2.826 ± 0.950 | 3.671 ± 0.479** |
Histopathology | ||||||||
- Bone marrow,decreased hematopoiesis | 0 | 0 | 0 | 4 | 0 | NE | NE | 0 |
- Spleen,decreased extramedullary | 0 | 0 | 0 | 2 | 0 | NE | NE | 0 |
- Testis,atrophy of Leydig cells | 0 | 0 | 0 | 5* |
|
|
|
|
- Mammary gland,atrophy of glands | 0 | 0 | 0 | 3 | 0 | NE | NE | 0 |
- Adrenal gland,hypertrophy of zona fasiculata | 1 | 1 | 0 | 8** | 0 | 1 | 1 | 2 |
- Pituitary gland,atrophy of basophilic cells | 0 | 0 | 0 | 1 | 0 | NE | NE | 0 |
- Liver,decreased hepatocytic glycogen | 1 | 0 | 1 | 8** | 0 | 0 | 1 | 2 |
- Organs in thoracic cavity,inflammation and granuloma | 1 | NE | NE | 0 | 0 | NE | NE | 0 |
NE not examined
* significant difference from control (p < 0.05)
** significant difference from control (p <0.01)
Table 7: Absolute and relative organ weights
Daily Dose (mg/kg/day) | Male | Female | ||||||
Control | 10 | 30 | 100 | Control | 10 | 30 | 100 | |
No. of animals | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Organ Weights | ||||||||
Prostate (ventral and dorsolateral) | ||||||||
mg | 1068 ± 188 | 1134 ± 179 | 1061 ± 189 | 827 ± 183* | - | - | - | - |
g/100 g | 0.237 ± 0.045 | 0.251 ± 0.031 | 0.236 ± 0.041 | 0.208 ± 0.039 | - | - | - | - |
Ventral prostate | ||||||||
mg | 631 ± 166 | 741 ± 110 | 676 ± 150 | 474 ± 112* | - | - | - | - |
g/100 g | 0.139 ± 0.034 | 0.164 ± 0.021 | 0.150 ± 0.030 | 0.120 ± 0.027 | - | - | - | - |
Seminal vesicle | ||||||||
g | 1.41 ± 0.19 | 1.43 ± 0.30 | 1.38 ± 0.24 | 1.02 ± 0.36* | - | - | - | - |
g/100 g | 0.312 ± 0.045 | 0.317 ± 0.069 | 0.307 ± 0.045 | 0.254 ± 0.079 | - | - | - | - |
Liver | ||||||||
g | 17.13 ± 2.18 | 16.90 ± 1.37 | 16.38 ± 2.85 | 14.10 ± 1.31** | - | - | - | - |
g/100 g | 3.778 ± 0.322 | 3.747 ± 0.179 | 3.623 ± 0.399 | 3.564 ± 0.271 | - | - | - | - |
Kidney | ||||||||
g | 3.02 ± 0.23 | 3.01 ± 0.18 | 3.00 ± 0.37 | 2.89 ± 0.30 | - | - | - | - |
g/100 g | 0.667 ± 0.021 | 0.671 ± 0.058 | 0.666 ± 0.064 | 0.729 ± 0.043* | - | - | - | - |
Heart | ||||||||
g | 1.28 ± 0.09 | 1.32 ± 0.08 | 1.28 ± 0.09 | 1.13 ± 0.13** | 0.87 ± 0.08 | 0.88 ± 0.05 | 0.82 ± 0.11 | 0.78 ± 0.06* |
g/100 g | 0.283 ± 0.013 | 0.293 ± 0.018 | 0.285 ± 0.011 | 0.286 ± 0.017 | 0.316 ± 0.015 | 0.319 ± 0.021 | 0.321 ± 0.024 | 0.308 ± 0.020 |
Spleen | ||||||||
g | 0.71 ± 0.08 | 0.70 ± 0.08 | 0.71 ± 0.10 | 0.59 ± 0.09* | - | - | - | - |
g/100 g | 0.158 ± 0.018 | 0.155 ± 0.015 | 0.158 ± 0.020 | 0.149 ± 0.016 | - | - | - | - |
Adrenals | ||||||||
mg | 58 ± 8 | 58 ± 11 | 56 ± 4 | 63 ± 9 | - | - | - | - |
g/100 g | 0.013 ± 0.002 | 0.013 ± 0.002 | 0.012 ± 0.001 | 0.016 ± 0.003** | - | - | - | - |
Brain | ||||||||
g | 2.17 ± 0.05 | 2.21 ± 0.09 | 2.23 ± 0.06 | 2.19 ± 0.07 | 2.03 ± 0.05 | 2.00 ± 0.06 | 2.05 ± 0.10 | 2.02 ± 0.08 |
g/100 g | 0.482 ± 0.034 | 0491 ± 0.032 | 0.498 ± 0.036 | 0.554 ± 0.035** | 0.742 ± 0.042 | 0.725 ± 0.044 | 0.809 ± 0.070* | 0.799 ± 0.039* |
* significantly different from control (p < 0.05)
** significantly different from control (p < 0.01)
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol
- Cas Number:
- 1478-61-1
- Molecular formula:
- C15H10F6O2
- IUPAC Name:
- 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol
- Test material form:
- not specified
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Not reported
- Stability under test conditions: Not reported
- Solubility and stability of the test substance in the solvent/vehicle: Confirmed
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: Not reported
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: Not reported
- Preliminary purification step (if any): Not reported
- Final dilution of a dissolved solid, stock liquid or gel: Not reported
- Final preparation of a solid: Not reported
FORM AS APPLIED IN THE TEST (if different from that of starting material): Not reported
OTHER SPECIFICS: n/a
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on species / strain selection:
- Crj:CD (SD) rats were purchased from Charles River, Japan, Inc (Shiga, Japan)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Crj:CD (SD) rats were purchased from Charles River, Japan, Inc (Shiga, Japan)
- Females (if applicable) nulliparous and non-pregnant: Not reported
- Age at study initiation: 8 weeks
- Weight at study initiation: ca. 310 - 340 g (males) and ca. 203 - 226 g (females)
- Fasting period before study: Not reported
- Housing: Housed individually in stainless stell wire-mesh cages.
- Diet (e.g. ad libitum): Ad libitum, commercial diet (MF, Oriental Yeast Co., Tokyo, Japan)
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: Not reported
DETAILS OF FOOD AND WATER QUALITY: Not reported
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 ºC
- Humidity (%): 55 ± 20 %
- Air changes (per hr): Not reported
- Photoperiod (hrs dark / hrs light): 12: 12 (light: dark)
IN-LIFE DATES: Not reported
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The volume of the olive oil that contained the chemical for gavage was 5 mL/kg.
- Vehicle:
- olive oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): n/a
- Mixing appropriate amounts with (Type of food): n/a
- Storage temperature of food: n/a
VEHICLE
- Justification for use and choice of vehicle (if other than water): olive oil - OECD recommended to aid solubility of test item.
- Concentration in vehicle: Not reported
- Amount of vehicle (if gavage): 5 mL/kg/bw
- Lot/batch no. (if required): Not reported
- Purity: Not reported - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- Dose / conc.:
- 30 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Chosen after completition of a range-finder test. Concentrations did not induce death or severe suffering.
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: No
- Post-exposure recovery period in satellite groups: n/a
- Section schedule rationale (if not random): Males were necropsied on Day 29. Females were necropsied after having been dosed for at least 29 days and killed ondays 30–33 to allow them to be killed in the diestrous stage or in the continuous same stage. - Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
- Cage side observations checked in Table 2 were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Weekly
BODY WEIGHT: Yes
- Time schedule for examinations: Twice weekly and before necropsy
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): n/a
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: n/a
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: n/a
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): n/a
- Time schedule for examinations: n/a
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations: n/a
- Dose groups that were examined: n/a
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At termination
- Anaesthetic used for blood collection: Yes (chemical name not reported)
- Animals fasted: Not specified
- How many animals: 20 animals per treatment group (10 males and 10 females, 80 animals in total)
- Parameters checked in Table 3 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At termination
- Animals fasted: Not specified
- How many animals: 20 animals per treatment group (10 males and 10 females, 80 animals in total)
- Parameters checked in Table 3 were examined.
URINALYSIS: No
- Time schedule for collection of urine: n/a
- Metabolism cages used for collection of urine: n/a
- Animals fasted: n/a
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: 4th week after test initialtion
- Dose groups that were examined: Control, 10, 30 and 100 mg/kg bw/day
- Battery of functions tested: sensory activity / grip strength / motor activity.
IMMUNOLOGY: No
- Time schedule for examinations: n/a
- How many animals: n/a
- Dose groups that were examined: n/a
OTHER: Hormone analysis (in serum), estrous cycle, spermatology and histopathology observations were also undertaken. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes - Table 4
HISTOPATHOLOGY: Yes - Table 4 - Statistics:
- Bartlett’s variance test was performed for the parametric data (body weight, food consumption, hematological data, clinical biochemical data, hormonal data, organ weight, sperm count, grip strength, and locomotor activity). Bartlett’s test revealed a homogeneous variance, so one-way analysis of variance was conducted and if the result of the one-way analysis was significant, Dunnett’s test was performed to compare the treated and the control groups. Data with an inhomogeneous variance shown by Bartlett’s test or nonparametric data (the number of stools, the number of urinary pools, and incidence rate of abnormal spermatozoa) were subjected to the Kruskal–Wallis rank test, and if a significant divergence was observed, a Dunnett’s approach was carried out. Incidence rates of abnormal estrous cycles, gross pathological findings, and histopathological findings were analyzed by Fisher’s “exact” probability test. In the evaluation of the examination results, when a divergence from the control was found at a significance level of 1 or 5%, it was regarded as a significant change.
A male rat in the control group was diagnosed as being the subject of an administration error on gross and histopathological examination. The error was thought to have happened just before day 22, based on changes in body weights and food consumption, so data that contained body weights at days 26 and 28, food consumption at days 22 and 28, and all organ weights of this rat were excluded from the statistical analysis.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Several male and female rats in the 100 mg/kg group showed salivation from the first week, and this sign disappeared within 90 min of administration. No other abnormal general findings were observed in any of the groups.
Salivation in the 100 mg/kg group was not found to be a sign of toxicity because this sign disappeared soon after administration and no other related changes were observed. - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A decrease in body weight gains was found in the male rat 100 mg/kg group and the female rat 30 and 100 mg/kg groups from the first week after administration and was accompanied by decreased food consumption.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- A decrease in body weight gains was found in the male rat 100 mg/kg group and the female rat 30 and 100 mg/kg groups from the first week after administration and was accompanied by decreased food consumption.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In male rats, white blood cell counts, total cholesterol, and albumin values decreased in the 100 mg/kg group. In female rats, cholinesterase and total cholesterol values decreased and total bilirubin values increased in the 100 mg/kg group.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In male rats, white blood cell counts, total cholesterol, and albumin values decreased in the 100 mg/kg group. In female rats, cholinesterase and total cholesterol values decreased and total bilirubin values increased in the 100 mg/kg group.
Serum T4 values increased in the 100 mg/kg groups of both sexes, but no changes in TSH were detected in any treated groups. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, the relative weights of kidney, adrenal, and brain increased signifcantly in the 100 mg/kg group and the absolute weights of prostate, ventral prostate, seminal vesicle, liver, heart, and spleen decreased in this group. In female rats, the relative brain weights increased significantly in the 30 and 100 mg/kg groups, and the absolute heart weights decreased in the 100 mg/kg group.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Dilatation of the large intestinal lumen was observed in 9 male and female rats in the 100 mg/kg groups, respectively.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In the male rats, the incidence of changes, such as atrophy of testicular Leydig cells, hypertrophy of the adrenal zona fasciculata, and decreased hepatocytic glycogen, was higher in the 100 mg/kg group than in the control group. In addition, decreased hematopoiesis in the bone marrow and spleen, atrophy of the mammary glands, and atrophy of pituitary basophilic cells were also observed in the 100 mg/kg group. In female rats, hypertrophy of the adrenal zona fasciculata and decreased hepatocytic glycogen were detected in several rats given the chemical.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Sperm analysis - no effects observed.
Estrous cycle - effects observed, treatment-related. Irregular estrous cycles were observed in the 30 and 100 mg/kg groups, and the diestrous stage continued in some animals. The mean duration of estrous cycles was prolonged in the 100 mg/kg group without statistical diverence (0 mg/kg group = 4.2 ± 0.4 days, 100 mg/kg group = 4.9 ± 0.9 days), and estrous cycling days were not measured in one and three of 10 rats in the 30 and 100 mg/kg groups, respectively, due to the irregularity of their estrous cycles.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Remarks on result:
- other:
Target system / organ toxicity
open allclose all
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 100 mg/kg bw/day (nominal)
- System:
- male reproductive system
- Organ:
- seminal vesicle
- other: Prostate weights
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 100 mg/kg bw/day (nominal)
- System:
- endocrine system
- Organ:
- adrenal glands
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Any other information on results incl. tables
Table 5 Mean body weight changes following 28 days of treatment
Dose Group |
Mean Initial Body Weight (g) |
Mean Terminal Body Weight (g) |
||
Male |
Female |
Male |
Female |
|
Control |
324 ± 14 |
211 ± 7 |
449 ± 27 |
274 ± 18 |
10 mg/kg/day |
324 ± 13 |
215 ± 11 |
451 ± 26 |
277 ± 18 |
30 mg/kg/day |
325 ± 15 |
213 ± 10 |
450 ± 33 |
255 ± 18* |
100 mg/kg/day |
326 ± 13 |
214 ± 11 |
396 ± 29** |
253 ± 15* |
* statistically different from control group (p < 0.05)
** statistically different from control group (p < 0.01)
Table 6: Selected haematology, clinical chemistry and pathology findings
Daily Dose (mg/kg bw/day) |
Male |
Female |
||||||
Control |
10 |
30 |
100 |
Control |
10 |
30 |
100 |
|
No. of animals |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
Haematology |
||||||||
- WBC (x103/mm3) |
12.28 ± 1.05 |
11.83 ± 2.66 |
11.17 ± 2.67 |
9.17 ± 2.46* |
8.59 ± 2.49 |
9.06 ± 2.15 |
9.28 ± 1.77 |
8.90 ± 1.84 |
Blood chemistry |
||||||||
- Cholinesterase (IU/L) |
54 ±18 |
56 ± 19 |
48 ± 11 |
50 ± 10 |
525 ± 163 |
537 ± 98 |
465 ± 236 |
300 ± 127* |
- Total cholesterol (mg/dL) |
69 ± 8 |
60 ± 12 |
60 ± 9 |
49 ± 7** |
69 ± 12 |
65 ± 7 |
60 ± 11 |
47 ± 5** |
- Total bilirubin (mg/dL) |
0.03 ± 0.02 |
0.02 ± 0.01 |
0.02 ± 0.01 |
0.03 ± 0.02 |
0.02 ± 0.01 |
0.01 ± 0.01 |
0.02 ± 0.01 |
0.04 ± 0.02** |
- Albumin (g/dL) |
3.00 ± 0.28 |
3.05 ± 0.12 |
3.05 ± 0.09 |
2.84 ± 0.11** |
3.51 ± 0.45 |
3.56 ±0.16 |
3.35 ± 0.33 |
3.30 ± 0.27 |
- T4 (ng/dL) |
3.704 ± 0.452 |
4.158 ± 0.826 |
4.061 ± 0.846 |
4.754 ± 0.762** |
2.397 ± 0.297 |
2.376 ± 0.443 |
2.826 ± 0.950 |
3.671 ± 0.479** |
Histopathology |
||||||||
- Bone marrow,decreased hematopoiesis |
0 |
0 |
0 |
4 |
0 |
NE |
NE |
0 |
- Spleen,decreased extramedullary |
0 |
0 |
0 |
2 |
0 |
NE |
NE |
0 |
- Testis,atrophy of Leydig cells |
0 |
0 |
0 |
5* |
|
|
|
|
- Mammary gland,atrophy of glands |
0 |
0 |
0 |
3 |
0 |
NE |
NE |
0 |
- Adrenal gland,hypertrophy of zona fasiculata |
1 |
1 |
0 |
8** |
0 |
1 |
1 |
2 |
- Pituitary gland,atrophy of basophilic cells |
0 |
0 |
0 |
1 |
0 |
NE |
NE |
0 |
- Liver,decreased hepatocytic glycogen |
1 |
0 |
1 |
8** |
0 |
0 |
1 |
2 |
- Organs in thoracic cavity,inflammation and granuloma |
1 |
NE |
NE |
0 |
0 |
NE |
NE |
0 |
NE not examined
* significant difference from control (p < 0.05)
** significant difference from control (p <0.01)
Table 7: Absolute and relative organ weights
Daily Dose (mg/kg/day) |
Male |
Female |
||||||
Control |
10 |
30 |
100 |
Control |
10 |
30 |
100 |
|
No. of animals |
9 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
Organ Weights |
||||||||
Prostate (ventral and dorsolateral) |
||||||||
mg |
1068 ± 188 |
1134 ± 179 |
1061 ± 189 |
827 ± 183* |
- |
- |
- |
- |
g/100 g |
0.237 ± 0.045 |
0.251 ± 0.031 |
0.236 ± 0.041 |
0.208 ± 0.039 |
- |
- |
- |
- |
Ventral prostate |
||||||||
mg |
631 ± 166 |
741 ± 110 |
676 ± 150 |
474 ± 112* |
- |
- |
- |
- |
g/100 g |
0.139 ± 0.034 |
0.164 ± 0.021 |
0.150 ± 0.030 |
0.120 ± 0.027 |
- |
- |
- |
- |
Seminal vesicle |
||||||||
g |
1.41 ± 0.19 |
1.43 ± 0.30 |
1.38 ± 0.24 |
1.02 ± 0.36* |
- |
- |
- |
- |
g/100 g |
0.312 ± 0.045 |
0.317 ± 0.069 |
0.307 ± 0.045 |
0.254 ± 0.079 |
- |
- |
- |
- |
Liver |
||||||||
g |
17.13 ± 2.18 |
16.90 ± 1.37 |
16.38 ± 2.85 |
14.10 ± 1.31** |
- |
- |
- |
- |
g/100 g |
3.778 ± 0.322 |
3.747 ± 0.179 |
3.623 ± 0.399 |
3.564 ± 0.271 |
- |
- |
- |
- |
Kidney |
||||||||
g |
3.02 ± 0.23 |
3.01 ± 0.18 |
3.00 ± 0.37 |
2.89 ± 0.30 |
- |
- |
- |
- |
g/100 g |
0.667 ± 0.021 |
0.671 ± 0.058 |
0.666 ± 0.064 |
0.729 ± 0.043* |
- |
- |
- |
- |
Heart |
||||||||
g |
1.28 ± 0.09 |
1.32 ± 0.08 |
1.28 ± 0.09 |
1.13 ± 0.13** |
0.87 ± 0.08 |
0.88 ± 0.05 |
0.82 ± 0.11 |
0.78 ± 0.06* |
g/100 g |
0.283 ± 0.013 |
0.293 ± 0.018 |
0.285 ± 0.011 |
0.286 ± 0.017 |
0.316 ± 0.015 |
0.319 ± 0.021 |
0.321 ± 0.024 |
0.308 ± 0.020 |
Spleen |
||||||||
g |
0.71 ± 0.08 |
0.70 ± 0.08 |
0.71 ± 0.10 |
0.59 ± 0.09* |
- |
- |
- |
- |
g/100 g |
0.158 ± 0.018 |
0.155 ± 0.015 |
0.158 ± 0.020 |
0.149 ± 0.016 |
- |
- |
- |
- |
Adrenals |
||||||||
mg |
58 ± 8 |
58 ± 11 |
56 ± 4 |
63 ± 9 |
- |
- |
- |
- |
g/100 g |
0.013 ± 0.002 |
0.013 ± 0.002 |
0.012 ± 0.001 |
0.016 ± 0.003** |
- |
- |
- |
- |
Brain |
||||||||
g |
2.17 ± 0.05 |
2.21 ± 0.09 |
2.23 ± 0.06 |
2.19 ± 0.07 |
2.03 ± 0.05 |
2.00 ± 0.06 |
2.05 ± 0.10 |
2.02 ± 0.08 |
g/100 g |
0.482 ± 0.034 |
0491 ± 0.032 |
0.498 ± 0.036 |
0.554 ± 0.035** |
0.742 ± 0.042 |
0.725 ± 0.044 |
0.809 ± 0.070* |
0.799 ± 0.039* |
* significantly different from control (p < 0.05)
** significantly different from control (p < 0.01)
Applicant's summary and conclusion
- Conclusions:
- The no adverse effect level (NOAEL) for the test item was determined to be 10 mg/kg bw/day, due to findings of reduced body weight gain and abnormal estrous cycles in the female rat 30 mg/kg bw/day group.
- Executive summary:
In a subacute repeat dose toxicity study (OECD 407), Bisphenol AF was administered to 30 male and 30 female Sprague-Dawley rats by oral gavage at dose levels of 10, 30 and 100 mg/kg bw/day for up to 28 consecutive days. In addition, control rats were dosed with vehicle (olive oil) alone for each test group.
A summary of adult responses to Bisphenol AF is described below;
Mortality - no treatment-related deaths were detected.
Clinical signs - clinical signs were generally confined to post-dose increased salvation and staining around the mouth for animals treated at 100 mg/kg/day. Regression of all signs was evident 90 minutes after treatment.
Behavioural assessments - open field observations did not reveal any treatment-related effects.
Functional performance - no treatment-related effects were evident for grip or motor activity.
Sensory reactivity assessments - no treatment-related effects were observed.
Bodyweight - significant (p< 0.01) reduced bodyweight gains were evident for males in the 100 mg/kg/day group during the treatment period. For females, bodyweight gain was significantly (p <0.05) reduced in the 30 and 100 mg/kg/day groups.
Haematology and blood chemistry - for males, a significant reduction in white blood cell count (p < 0.05), cholinesterase and albumin (p < 0.01) was observed in the 100 mg/kg bw/day treatment group. Further, a significant (p < 0.01) increase in T4 hormone was also observed in the same treatment group. For females, a significant decrease in cholinesterase (p < 0.05) and total cholesterol (p < 0.01) was observed in the 100 mg/kg bw/day treatment group. Further, a significant (p < 0.01) increase in total bilirubin and T4 hormone was also observed in the same treatment group.
Oestrous cycle assessment - irregular estrous cycles were observed in the 30 and 100 mg/kg groups, and the diestrous stage continued in some animals. The mean duration of estrous cycles was prolonged in the 100 mg/kg group without statistical difference.
Necropsy - dilatation of the large intestinal lumen was observed in 9 male and female rats in the 100 mg/kg groups, respectively.
Organ weights - in males, the relative weights of kidney, adrenal, and brain increased significantly in the 100 mg/kg group and the absolute weights of prostate, ventral prostate, seminal vesicle, liver, heart, and spleen decreased in the same group. In female rats, the relative brain weights increased significantly in the 30 and 100 mg/kg groups, and the absolute heart weights decreased in the 100 mg/kg group.
Histopathological changes - in the male rats, the incidence of changes, such as atrophy of testicular Leydig cells, hypertrophy of the adrenal zona fasciculata, and decreased hepatocytic glycogen, was statistically significantly higher in the 100 mg/kg group than in the control group. In addition, decreased hematopoiesis in the bone marrow and spleen, atrophy of the mammary glands, and atrophy of pituitary basophilic cells were also observed in the 100 mg/kg group. In female rats, hypertrophy of the adrenal zona fasciculata and decreased hepatocytic glycogen were detected in several rats at each dose level, although these changes were not statistically significantly.
In conclusion, the No Observed Adverse Effect Level (NOAEL) for systemic toxicity was 10 mg/kg bw/day due to findings of reduced body weight gain and abnormal estrous cycles in the female rat treated at 30 mg/kg bw/day.
This subacute repeat dose toxicity study in the rat is acceptable and satisfies the guideline requirements for an OECD 417 in the rat.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.